Introduction

Breast cancer is the most common cancer among Chinese women for several years. It is also the main cause of cancer death for females (1,2). For breast cancer patients who had undergone breast-conserving surgery or a part of patients received modified radical mastectomy, radiotherapy plays a key role in the multidisciplinary treatment (3-5). However, it remains a controversy whether it is necessary to carry out prophylactic internal mammary nodes irradiation (IMNI). This review will focus on this topic. In our opinion, the total risk of relapse should be considered during the decision-making on IMNI; in particular, IMNI is recommended for high-risk patients whose tumor is located at the central/medial area or in patients with positive axillary lymph nodes.

Keywords: Breast cancer; radiotherapy; internal mammary nodes (IMN)
II, and III breast cancer patients in whom the tumors were located in the central area and the medial area, they were randomized into regional lymph nodes radiotherapy group (IMN plus supraclavicular lymph nodes) and non-regional lymph nodes radiotherapy group (control group). A total of 4,004 patients were enrolled. After 10 years of follow-up, the disease-free survival (DFS) in the regional lymph nodes radiotherapy group and control group was 72.1% and 69.1% (P=0.04), the distant metastasis-free survival (DMFS) was 78% and 75% (P=0.02), and the OS was 82.3% and 80.7% (P=0.06). This study indicated that the loco-regional lymph nodes radiotherapy, in particular IMNI, had a marginal positive effect on OS, and DFS was significantly improved.

The MA.20 study in Canada was another multicenter RCT that was similar to EORTC 22922 (12), although the primary endpoint of that study was to explore the effect of whole regional lymph nodes radiotherapy following breast-conserving surgery on the long-term survival rather than discussing the value of IMNI. A total of 1,832 patients who had undergone breast-conserving surgery from 2000 to 2007 were enrolled. The inclusion criteria were as follows: patients at high risk of relapse no matter the axillary lymph nodes were positive or negative. The risk factors included: the primary tumor was larger than 5 cm in size; the number of the dissected axillary lymph nodes were less than 10; in histological grade 3; ER-negative; and/or positive vascular tumor thrombus. All patients were randomized into breast radiotherapy following breast-conserving surgery group and breast plus regional lymph nodes radiotherapy group; in the latter group, the regional lymph nodes radiotherapy was defined as IMN plus axillary lymph nodes plus supraclavicular lymph nodes. After 10 years of follow-up, the DFS in the regional lymph nodes radiotherapy group and control group was 82.0% and 77.0% (P=0.01) and the OS was 82.8% and 81.8% (P=0.38). Although the MA.20 study showed that the regional radiotherapy (including IMNI) was beneficial for the DFS, the high local recurrence in no regional radiotherapy group was a notable problem in that study (Table 1). Among patients with recurrent disease, the lesions were located in the axillary lymph nodes in 63% of the patients and in the supraclavicular lymph nodes in 27% of the patients. Based on such prognostic data, we are doubtful about the standards and quality of axillary lymph nodes dissection in the MA.20 study, because the recurrence rate in axillary lymph nodes following complete axillary lymph nodes dissection is often below 5% in general. There is also a possibility that the study included more patients with high risk, thus has a higher recurrence rate. Although the MA.20 study did not confirm that the loco-regional lymph nodes radiotherapy could benefit the OS in patients who had undergone breast-conserving surgery, the regional radiotherapy group did lower the loco-regional relapse (10-year locoregional DFS: IMLN/SCV LN RT 95.2% vs. no IMLN/SCV LN RT 92.2%; P=0.009). Further follow-up of the study may reveal whether there will be OS benefit after longer follow-up.

In contrast to the above two positive conclusions, Hennequin et al., a French team, carried out a multicenter randomized controlled trial on IMNI in 1991 and did not demonstrate that IMNI could benefit the patients in terms of local control or long-term survival (10). Stage I/II breast cancer patients with positive axillary lymph nodes or patients with central/medial tumors were enrolled in this study. All patients received postoperative irradiation of the chest wall and supraclavicular lymph nodes (irradiation of the apex of the axillary region in patients with positive axillary lymph nodes) and were randomly assigned to receive IMNI or not. The primary endpoint of the study was OS. After 10 years of follow-up, the DFS was 53.2% and 49.9%,
respectively, in the IMNI group and control group, and the OS was 62.6% and 59.3%. Both DFS and OS showed no significant difference between these two groups. This trial failed to demonstrate a survival benefit for IMN irradiation. The findings were obviously contrary to the results of EORTC 22922 and MA.20. Notably, although the follow-up period was about 10 years in all these three studies, the OS was significantly lower in the French study than in the other two studies, which might because the French study was a relatively earlier study and the systemic treatment was somehow different from those in the other two studies.

A Danish group recently published the results of a large cohort study on IMNI (17); unlike the above three studies, the Danish research was not a randomized controlled trial; all the enrolled breast cancer patients were lymph nodes positive patients who had undergone breast-conserving surgery or modified radical mastectomy. According to the long adopted radiotherapy practice in this group, the breast and chest wall were irradiated, with the subclavicular/subclavicular lymph nodes and axillary lymph nodes stations II/III. To avoid radiotherapy-associated cardiac toxicity, IMNI was performed in patients with right-sided disease, in whom the first to fourth intercostal spaces were irradiated by using electron-beam irradiation. Patients with left-sided disease were allocated to no IMNI. The primary endpoint was OS. A total of 3,377 patients were enrolled in this study. With a median of 8.9 years of follow-up time, the 8-year OS rates were 75.9% with IMNI versus 72.2% without IMNI. The effect of IMNI was more pronounced in patients at high risk of internal mammary nodes metastasis (the primary tumor was located in the central/medial area and/or the number of axillary lymph nodes was more than 4). Although the Danish research was not a prospective study, it met the “real-world” features (18). It revealed that IMNI could improve the OS (by 3.7% in 8 years); further analysis of the patients proportion showed that: there were more low-risk patients; 90% of the tumors were smaller than 5 cm in size; 60% of the patients had 1 to 3 positive ALNs; and 60% of the tumors were located in the lateral quadrant of the breast. On this basis, we can speculate that high-risk patients might benefit more from IMNI. As we know, targeted therapy with Herceptin is more feasible in breast cancer patients with HER2 overexpression (19); similarly, it is a new topic to screen high-risk patients or patients may benefit from IMNI in a simpler and faster way. Table 1 is a summary of the above four studies.

Based on the above three randomized controlled trials, it is difficult to evaluate the role of IMNI in the postoperative radiotherapy for breast cancer patients. Some recent observational studies presented evidences from the real world. Will the findings of these real world studies differed from the results of RCTs? In addition, with advances in technology and equipment, will IMNI bring new benefits to breast cancer patients? A recently published systematic review explored these questions (7). A total of four RCTs, four non-RCTs, seven retrospective studies, and 1 previously published meta-analysis were included in this systematic review. According to the authors, in some old RCTs, the differences in prognosis could not be identified in patients who had received IMNI or not due to limitations in technology or equipment (compared with the modern equipment) (7,10,20). Some newer RCTs, in contrast, have suggested that loco-regional lymph nodes radiotherapy (including IMNI) could improve the prognosis of patients by lowering the recurrence rate and even increasing the OS (7,11,12). Some non-RCTs and retrospective studies from the real world also indicated that radiotherapy (including IMNI) improved the prognosis (17,21,22). According to some recent studies, in the background of the wide use of modern radiotherapy technology and equipment, radiotherapy (including IMNI) increased the pulmonary complications; however, these adverse reactions were often mild. In addition, few data on cardiac toxicity have been available (7). The systematic review concluded that, based on the currently available evidences, the benefits and harms of postoperative radiotherapy should be balanced for each patient, and IMNI is recommended for high-risk patients whose tumor is located at the central/medial area or in patients with positive axillary lymph nodes.

Conclusions
In summary, the total risk of relapse should be considered during the decision-making on IMN radiotherapy; in particular, IMNI is recommended for high-risk patients whose tumor is located at the central/medial area or in patients with positive axillary lymph nodes.

Acknowledgements
None.

Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.
References


Cite this article as: Zhou ZR, Yang ZZ, Yu XL, Guo XM. Is internal mammary nodes irradiation as a part of breast cancer postoperative radiotherapy necessary? J Thorac Dis 2016;8(11):3427-3430. doi: 10.21037/jtd.2016.11.12